{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:53:14Z","timestamp":1793040794736,"version":"4.5.0"},"reference-count":65,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:00:00Z","timestamp":1760659200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>Cannabinoids, present in <jats:italic>Cannabis sativa<\/jats:italic>, modulate the signaling and receptor expression of the endocannabinoid system (ECS), potentially impacting various skin conditions. However, current evaluations of their clinical effectiveness remain largely descriptive. This study aimed to quantitatively assess the effectiveness of cannabinoids, including <jats:italic>Cannabis sativa<\/jats:italic> extracts, in treating dermatologic disorders.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design<\/jats:title><jats:p>Systematic review and meta-analysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Data sources<\/jats:title><jats:p>PubMed, Embase, Scopus, Web of Science, and CENTRAL from inception to 30 June 2024.<\/jats:p><\/jats:sec><jats:sec><jats:title>Eligibility criteria for selecting studies<\/jats:title><jats:p>We included randomized controlled trials and observational studies that evaluated the efficacy or effectiveness of medical cannabis or cannabinoid-based interventions in managing dermatologic conditions, regardless of the comparator type.<\/jats:p><\/jats:sec><jats:sec><jats:title>Data extraction and synthesis<\/jats:title><jats:p>Two reviewers independently extracted data and assessed risk of bias. Outcomes were categorized into subjective outcomes, objective outcomes, and disease-specific composite scores. Meta-analyses used standard mean differences (SMDs) with 95% confidence intervals (CIs). Study quality was assessed using RoB 2 and ROBINS-I tools.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We included 3,359 participants from eleven randomized controlled trials, three quasi-experimental studies, and three observational studies. Interventions included topical formulations of cannabis extract ointment, cannabidiol, N-acylethanolamine (PEA), alkylamides, and HU-210. A statistically significant reduction in pruritus was observed among participants treated with cannabinoids (SMD = \u22120.29, 95% CI: \u22120.52 to \u22120.06, I<jats:sup>2<\/jats:sup> = 0%). No significant effects were found for skin dryness (SMD = \u22120.22, 95% CI: \u22120.58 to 0.14, I<jats:sup>2<\/jats:sup> = 20%), erythema (SMD = \u22120.33, 95% CI: \u22120.65 to 0.00, I<jats:sup>2<\/jats:sup> = 0%), or quality of life (SMD = \u22120.15, 95% CI: \u22120.64 to 0.34, I<jats:sup>2<\/jats:sup> = 58%). Disease-specific scores for atopic dermatitis (SMD = \u22120.19, 95% CI: \u22120.44 to 0.05, I<jats:sup>2<\/jats:sup> = 0%) and transepidermal water loss (SMD = 0.16, 95% CI: \u22120.60 to 0.93, I<jats:sup>2<\/jats:sup> = 68%) also showed no significant differences.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Cannabinoids produced a modest but statistically significant reduction in pruritus, suggesting clinical relevance for symptom management. However, no significant benefits were observed for other dermatologic outcomes. Larger, standardized randomized trials are needed to clarify their therapeutic potential in dermatology.<\/jats:p><\/jats:sec><jats:sec><jats:title>Systematic Review Registration<\/jats:title><jats:p>identifier CRD42023397189.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2025.1609667","type":"journal-article","created":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T05:29:20Z","timestamp":1760678960000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Cannabis and cannabinoids in dermatology: a systematic review and meta-analysis of quantitative outcomes"],"prefix":"10.3389","volume":"16","author":[{"given":"Pim","family":"Sermsaksasithorn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanawin","family":"Nopsopon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chatpol","family":"Samuthpongtorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Korn","family":"Chotirosniramit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krit","family":"Pongpirul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1111\/vde.12456","article-title":"Ultramicronized palmitoylethanolamide counteracts the effects of compound 48\/80 in a canine skin organ culture model","volume":"28","author":"Abramo","year":"2017","journal-title":"Vet. Dermatol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.ejim.2018.01.001","article-title":"Medical use of cannabis and cannabinoids containing products - regulations in Europe and North America","volume":"49","author":"Abuhasira","year":"2018","journal-title":"Eur. J. Intern Med."},{"key":"B3","first-page":"1389","article-title":"The safety and efficacy of 3% Cannabis seeds extract cream for reduction of human cheek skin sebum and erythema content","volume":"28","author":"Ali","year":"2015","journal-title":"Pak J. Pharm. Sci."},{"key":"B4","doi-asserted-by":"publisher","first-page":"531","DOI":"10.36721\/PJPS.2020.33.2.REG.531-535.1","article-title":"The improvement on the skin surface by a new type of dermocosmetic loaded plant extract: a split face skin topographic study","volume":"33","author":"Ali","year":"2020","journal-title":"Pak J. Pharm. Sci."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1016\/j.jaad.2020.01.036","article-title":"Cannabinoids for the treatment of chronic pruritus: a review","volume":"82","author":"Avila","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"927","DOI":"10.2147\/CCID.S286411","article-title":"Therapeutic potential of cannabidiol (CBD) for skin health and disorders","volume":"13","author":"Baswan","year":"2020","journal-title":"Clin. Cosmet. Investig. Dermatol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.tips.2009.05.004","article-title":"The endocannabinoid system of the skin in health and disease: novel perspectives and therapeutic opportunities","volume":"30","author":"B\u00edr\u00f3","year":"2009","journal-title":"Trends Pharmacol. Sci."},{"key":"B8","doi-asserted-by":"publisher","first-page":"2478","DOI":"10.3390\/molecules23102478","article-title":"Cannabinoid delivery systems for pain and inflammation treatment","volume":"23","author":"Bruni","year":"2018","journal-title":"Molecules"},{"key":"B9","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1080\/09546630510035832","article-title":"Efficacy of dietary hempseed oil in patients with atopic dermatitis","volume":"16","author":"Callaway","year":"2005","journal-title":"J. Dermatol. Treat."},{"key":"B10","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1148\/75.3.406","article-title":"Quantitative and qualitative evaluation of skin erythema I. Technic of measurement and description of the reaction","volume":"75","author":"Chu","year":"1960","journal-title":"Radiology"},{"key":"B11","doi-asserted-by":"publisher","first-page":"e6835","DOI":"10.32872\/cpe.6835","article-title":"Has the time come to stop using the \u201cstandardised mean difference\u201d","volume":"3","author":"Cuijpers","year":"2021","journal-title":"Clin. Psychol. Eur."},{"key":"B12","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1038\/nrd1495","article-title":"The endocannabinoid system and its therapeutic exploitation","volume":"3","author":"Di Marzo","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"key":"B13","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1007\/s00011-003-1162-z","article-title":"Histamine induced responses are attenuated by a cannabinoid receptor agonist in human skin","volume":"52","author":"Dvorak","year":"2003","journal-title":"Inflamm. Res."},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.5070\/d3246040706","article-title":"Cannabinoids in dermatology: a scoping review","volume":"24","author":"Eagleston","year":"2018","journal-title":"Dermatol Online J."},{"key":"B15","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1111\/j.1468-3083.2007.02351.x","article-title":"Adjuvant treatment of atopic eczema: assessment of an emollient containing N-palmitoylethanolamine (ATOPA study)","volume":"22","author":"Eberlein","year":"2008","journal-title":"J. Eur. Acad. Dermatol Venereol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.3390\/ph16071049","article-title":"The skin and natural cannabinoids-topical and transdermal applications","volume":"16","author":"Filipiuc","year":"2023","journal-title":"Pharm. (Basel)"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000029840","article-title":"Direct and non-direct measurement techniques for analysis of skin surface topography","volume":"12","author":"Fischer","year":"1999","journal-title":"Skin Pharmacol. Appl. Skin Physiology"},{"key":"B18","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.jclinepi.2019.11.011","article-title":"P value-driven methods were underpowered to detect publication bias: analysis of Cochrane review meta-analyses","volume":"118","author":"Furuya-Kanamori","year":"2020","journal-title":"J. Clin. Epidemiol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1111\/exd.12414","article-title":"Cannabinoid 1 receptors in keratinocytes attenuate fluorescein isothiocyanate-induced mouse atopic-like dermatitis","volume":"23","author":"Gaffal","year":"2014","journal-title":"Exp. Dermatol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1111\/jocd.14263","article-title":"Novel cannabidiol aspartame combination treatment (JW-100) significantly reduces ISGA score in atopic dermatitis: results from a randomized double-blinded placebo-controlled interventional study","volume":"21","author":"Gao","year":"2022","journal-title":"J. Cosmet. Dermatol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1097\/YIC.0000000000000382","article-title":"Tetrahydrocannabinol fails to reduce hair pulling or skin picking: results of a double blind, placebo controlled study of dronabinol","volume":"37","author":"Grant","year":"2022","journal-title":"Int. Clin. Psychopharmacol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"327","DOI":"10.2165\/00003088-200342040-00003","article-title":"Pharmacokinetics and pharmacodynamics of cannabinoids","volume":"42","author":"Grotenhermen","year":"2003","journal-title":"Clin. Pharmacokinet."},{"key":"B22","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1002\/hep.26598","article-title":"Cannabinoid receptor 2 counteracts interleukin-17-induced immune and fibrogenic responses in mouse liver","volume":"59","author":"Guillot","year":"2014","journal-title":"Hepatology"},{"key":"B23","doi-asserted-by":"publisher","first-page":"2703","DOI":"10.1111\/jocd.14352","article-title":"Cannabinoids for skin diseases and hair regrowth","volume":"20","author":"Gupta","year":"2021","journal-title":"J. Cosmet. Dermatol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Statistics Med."},{"key":"B25","doi-asserted-by":"publisher","first-page":"978289","DOI":"10.1155\/2013\/978289","article-title":"Skin parameter map retrieval from a dedicated multispectral imaging system applied to dermatology\/cosmetology","volume":"2013","author":"Jolivot","year":"2013","journal-title":"Int. J. Biomed. Imaging"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-3-030-21737-2_1","article-title":"Endocannabinoid system components: overview and tissue distribution","volume":"1162","author":"Joshi","year":"2019","journal-title":"Adv. Exp. Med. Biol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"e401","DOI":"10.1111\/ijd.12841","article-title":"Topical cannabinoid receptor 1 agonist attenuates the cutaneous inflammatory responses in oxazolone-induced atopic dermatitis model","volume":"54","author":"Kim","year":"2015","journal-title":"Int. J. Dermatol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"202","DOI":"10.3390\/pharmaceutics16020202","article-title":"Cutaneous delivery and biodistribution of cannabidiol in human skin after topical application of colloidal formulations","volume":"16","author":"Lapteva","year":"2024","journal-title":"Pharmaceutics"},{"key":"B29","doi-asserted-by":"publisher","first-page":"790712","DOI":"10.3389\/fphar.2022.790712","article-title":"CB2R deficiency exacerbates imiquimod-induced psoriasiform dermatitis and itch through the neuro-immune pathway","volume":"13","author":"Li","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"9472","DOI":"10.3390\/ijms22179472","article-title":"The endocannabinoid system: a potential target for the treatment of various diseases","volume":"22","author":"Lowe","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"B31","doi-asserted-by":"publisher","first-page":"210","DOI":"10.3390\/ph15020210","article-title":"Cannabis-based products for the treatment of skin inflammatory diseases: a timely review","volume":"15","author":"Martins","year":"2022","journal-title":"Pharm. (Basel)."},{"key":"B32","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s11154-021-09682-w","article-title":"The effects of cannabis and cannabinoids on the endocrine system","volume":"23","author":"Meah","year":"2022","journal-title":"Rev. Endocr. Metabolic Disord."},{"key":"B33","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s40257-018-0410-5","article-title":"Cannabinoids: potential role in inflammatory and neoplastic skin diseases","volume":"20","author":"Milando","year":"2019","journal-title":"Am. J. Clin. Dermatology"},{"key":"B34","doi-asserted-by":"publisher","first-page":"4775","DOI":"10.1111\/bph.15672","article-title":"Chronic itch: emerging treatments following new research concepts","volume":"178","author":"Misery","year":"2021","journal-title":"Br J Pharmacol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"k4817","DOI":"10.1136\/bmj.k4817","article-title":"When continuous outcomes are measured using different scales: guide for meta-analysis and interpretation","volume":"364","author":"Murad","year":"2019","journal-title":"BMJ (Clinical Res. ed)"},{"key":"B36","doi-asserted-by":"publisher","first-page":"22","DOI":"10.5021\/ad.2016.28.1.22","article-title":"Selective cannabinoid Receptor-1 agonists regulate mast cell activation in an oxazolone-induced atopic dermatitis model","volume":"28","author":"Nam","year":"2016","journal-title":"Ann. Dermatol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.jdermsci.2017.05.015","article-title":"Echinacea purpurea-derived alkylamides exhibit potent anti-inflammatory effects and alleviate clinical symptoms of atopic eczema","volume":"88","author":"Ol\u00e1h","year":"2017","journal-title":"J. Dermatol Sci."},{"key":"B38","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1124\/pr.58.3.2","article-title":"The endocannabinoid system as an emerging target of pharmacotherapy","volume":"58","author":"Pacher","year":"2006","journal-title":"Pharmacol. Rev."},{"key":"B39","doi-asserted-by":"publisher","first-page":"3344","DOI":"10.3390\/ijms23063344","article-title":"Cannabinoids: therapeutic use in clinical practice","volume":"23","author":"Pagano","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"B40","doi-asserted-by":"publisher","first-page":"e93","DOI":"10.7417\/CT.2019.2116","article-title":"A therapeutic effect of cbd-enriched ointment in inflammatory skin diseases and cutaneous scars","volume":"170","author":"Palmieri","year":"2019","journal-title":"Clin. Ter."},{"key":"B41","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/s0029-7844(97)00305-0","article-title":"Research design and methods of quantitative synthesis of medical evidence","volume":"90","author":"Peipert","year":"1997","journal-title":"Obstet. Gynecol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"129","DOI":"10.3390\/cosmetics10050129","article-title":"Cannabinoids for the treatment of hair, scalp, and skin disorders: a systematic review","volume":"10","author":"Popp","year":"2023","journal-title":"Cosmetics"},{"key":"B43","doi-asserted-by":"publisher","first-page":"4102","DOI":"10.3390\/cells11244102","article-title":"Cannabinoid compounds as a pharmacotherapeutic option for the treatment of non-cancer skin diseases","volume":"11","author":"Ramer","year":"2022","journal-title":"Cells"},{"key":"B44","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1159\/000536670","article-title":"Efficacy of topical palmitoylethanolamide (Levagen+) for the management of eczema symptoms: a double-blind, comparator-controlled, randomized clinical trial","volume":"36","author":"Rao","year":"2023","journal-title":"Skin Pharmacol. Physiology"},{"key":"B45","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.bcp.2018.08.022","article-title":"The endocannabinoid system of the skin. A potential approach for the treatment of skin disorders","volume":"157","author":"Rio","year":"2018","journal-title":"Biochem. Pharmacol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/s0304-3959(02)00401-3","article-title":"Cannabinoid agonists attenuate capsaicin-induced responses in human skin","volume":"102","author":"Rukwied","year":"2003","journal-title":"Pain"},{"key":"B47","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1002\/ptr.6400","article-title":"Cannabis sativa L. extract and cannabidiol inhibit in vitro mediators of skin inflammation and wound injury","volume":"33","author":"Sangiovanni","year":"2019","journal-title":"Phytother. Res."},{"key":"B48","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1159\/000505028","article-title":"An evaluation of regulatory regimes of medical cannabis: what lessons can be learned for the UK? Medical cannabis and cannabinoids","volume":"3","author":"Schlag","year":"2020","journal-title":"Med. Cannabis Cannabinoids"},{"key":"B49","doi-asserted-by":"publisher","first-page":"e075007","DOI":"10.1136\/bmjopen-2023-075007","article-title":"Cannabis and cannabinoids in dermatology: protocol for a systematic review and meta-analysis of quantitative outcomes","volume":"13","author":"Sermsaksasithorn","year":"2023","journal-title":"BMJ Open"},{"key":"B50","doi-asserted-by":"publisher","first-page":"g7647","DOI":"10.1136\/bmj.g7647","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation","volume":"350","author":"Shamseer","year":"2015","journal-title":"BMJ (Clinical Res. ed)"},{"key":"B51","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/j.clindermatol.2021.05.006","article-title":"Cannabis and the skin","volume":"39","author":"Shao","year":"2021","journal-title":"Clin. dermatology"},{"key":"B52","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1080\/09546634.2019.1675854","article-title":"The potential role of cannabinoids in dermatology","volume":"31","author":"Sheriff","year":"2020","journal-title":"J. Dermatol. Treat."},{"key":"B53","doi-asserted-by":"publisher","first-page":"100095","DOI":"10.1016\/j.xjidi.2022.100095","article-title":"Cannabinoids for the treatment of dermatologic conditions","volume":"2","author":"Sivesind","year":"2022","journal-title":"JID Innov."},{"key":"B54","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1002\/art.42510","article-title":"Efficacy and safety of lenabasum, a cannabinoid type 2 receptor agonist, in a phase 3 randomized trial in diffuse cutaneous systemic sclerosis","volume":"75","author":"Spiera","year":"2023","journal-title":"Arthritis Rheumatol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.jdermsci.2005.01.007","article-title":"Distribution of cannabinoid receptor 1 (CB1) and 2 (CB2) on sensory nerve fibers and adnexal structures in human skin","volume":"38","author":"St\u00e4nder","year":"2005","journal-title":"J Dermatol Sci."},{"key":"B56","first-page":"97","article-title":"Efficacy and tolerance of the cream containing structured physiological lipids with endocannabinoids in the treatment of uremic pruritus: a preliminary study","volume":"13","author":"Szepietowski","year":"2005","journal-title":"Acta Dermatovenerol Croat."},{"key":"B57","doi-asserted-by":"publisher","first-page":"129","DOI":"10.23822\/EurAnnACI.1764-1489.79","article-title":"A successful topical treatment for cutaneous inflammatory diseases:an additional or alternative therapy to topical steroids","volume":"51","author":"Tammaro","year":"2019","journal-title":"Eur. Ann. Allergy Clin Immunol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1080\/08820139.2022.2083973","article-title":"The effects of cannabinoid agonist, heat shock protein 90 and nitric oxide synthase inhibitors on increasing IL-13 and IL-31 levels in chronic pruritus","volume":"51","author":"Todurga Seven","year":"2022","journal-title":"Immunol. Invest"},{"key":"B59","doi-asserted-by":"publisher","first-page":"639","DOI":"10.2340\/00015555-2593","article-title":"Efficacy of body lotion containing N-palmitoylethanolamine in subjects with chronic pruritus due to dry skin: a dermatocosmetic study","volume":"97","author":"Visse","year":"2017","journal-title":"Acta Derm. Venereol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"301","DOI":"10.2478\/acph-2024-0014","article-title":"Clinical application of hempseed or flaxseed oil-based lyotropic liquid crystals: evaluation of their impact on skin barrier function","volume":"74","author":"Vitek","year":"2024","journal-title":"Acta Pharm."},{"key":"B61","doi-asserted-by":"publisher","first-page":"2651","DOI":"10.1016\/j.jid.2022.03.029","article-title":"Safety and efficacy of Lenabasum, a cannabinoid receptor type 2 agonist, in patients with dermatomyositis with refractory skin disease: a randomized clinical trial","volume":"142","author":"Werth","year":"2022","journal-title":"J. Invest Dermatol"},{"key":"B62","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1146\/annurev-med-050214-013454","article-title":"Marijuana legalization: impact on physicians and public health","volume":"67","author":"Wilkinson","year":"2016","journal-title":"Annu. Rev. Med."},{"key":"B63","doi-asserted-by":"publisher","first-page":"16523","DOI":"10.3390\/ijms242216523","article-title":"Cannabinoids and their receptors in skin diseases","volume":"24","author":"Yoo","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B64","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.2147\/CIA.S65448","article-title":"N-palmitoylethanolamine and N-acetylethanolamine are effective in asteatotic eczema: results of a randomized, double-blind, controlled study in 60 patients","volume":"9","author":"Yuan","year":"2014","journal-title":"Clin. Interv. Aging"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1609667\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T05:29:22Z","timestamp":1760678962000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1609667\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,17]]},"references-count":65,"alternative-id":["10.3389\/fphar.2025.1609667"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1609667","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,17]]},"article-number":"1609667"}}